OncoSec Medical Incorporated · OTC:ONCSQ

OncoSec Medical — Investor Presentation (October 2017)

21 slides from OncoSec Medical's investor presentation, October 2017

  1. Slide 1: Arming the Immune System to Fight Cancer

    ARMING THE IMMUNE SYSTEM TO FIGHT CANCER Targeting the Tumor Locally October 2017 | NASDAQ:ONCS

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    // Cautionary Note Regarding Forward-Looking Statements To the extent statements contained in the following presentations are not descriptions of historical facts regarding OncoSec Medical Incorporated, they should be considered “forward-looking statements,” as described in the Private Securities Li

  3. Slide 3: A Near-Term Investment Opportunity

    // OncoSec A Near-Term Investment Opportunity • ImmunoPulse® IL-12 for stage III/IV relapsed/refractory melanoma positioned for accelerated approval Initial data mid-2018, seek feedback on accelerated approval Potential approval in 2019 via accelerated pathway Global PISCES trial in melanoma • Im

  4. Slide 4: ~70-90% of Anti-PD-1 Patients Have No Response

    // ~70-90% of Anti-PD-1 Patients Have No Response Significant Patient Population Checkpoint Inhibitors Dramatically Increase Tumor Type % Non-Responders Survival in Patients with HOT Tumors Largely Ineffective in COLD Tumors Melanoma ~60-80% Triple Negative Breast ~95%1 Renal Cell Carcinoma ~71%2 Im

  5. Slide 5: Interleukin-12 (IL-12): Local Administration Potent and Safe

    // Interleukin-12 (IL-12): Local Administration Potent and Safe Tavokinogene telsaplasmid encodes IL-12 • Potent, well-characterized proinflammatory cytokine • Shown to make the tumor micro-environment immunogenic • Targets the tumor to signal and traffic immunomodulatory molecules locally while enh

  6. Slide 6: Plasmid IL-12 + Electroporation Significantly Reduces Tumor Volume in Mouse Melanoma Model

    // Plasmid IL-12 + Electroporation Significantly Reduces Tumor Volume vs Plasmid or Protein IL-12 in a Mouse Model of Melanoma 1 5 0 0 1 5 0 0 P B S 3 ) 3 ) m m R e c o m b in a n t IL - 1 2 ( 5 u g ) N o T r e a tm e n t ( m ( m E m p ty p la s m id v e c to r w ith E P 1 0 0 0 1 0 0 0 e e p IL 1 2

  7. Slide 7: ImmunoPulse IL-12 Phase 2 Monotherapy Data Delivers CRs in Metastatic Melanoma

    // ImmunoPulse® IL-12 Phase 2 Monotherapy Data Delivers CRs in Metastatic Melanoma 35% 19% 69% 50% Best Overall Complete Disease Complete Regression Response Response Control Rate in at Least One Lesion Data from our multi-center Phase 2 trial of ImmunoPulse® IL-12 (treated on a 90-day cycle, on Day

  8. Slide 8: Phase 2 Monotherapy Addendum Data Demonstrated Similar Disease Control Rates and Equivalent Safety

    // ImmunoPulse® IL-12 Phase 2 Monotherapy Addendum Data Demonstrated Similar Disease Control Rates and Equivalent Safety # OMS-I102 patients were selected based on biomarker data, thus the PISCES /Keynote 695 trial to address the patient populations *OMS-I100 was modified skin RECIST and OMS-I102 RE

  9. Slide 9: ImmunoPulse IL-12 Resensitizes Melanoma Tumors to Anti-PD-1

    // ImmunoPulse® IL-12 Resensitizes Melanoma Tumors to Anti-PD-1 Converting “cold” tumors to “hot” • Patients who respond to anti-PD-1 agents “Cold” Tumor “Hot”Tumor will generally have a “hot” or “inflamed” tumor, defined by key biomarkers: – High expression of PD-L1 on the tumor cell surface – High

  10. Slide 10: ImmunoPulse IL-12 Converts Cold to Hot in Other Solid Tumor Types

    // ImmunoPulse® IL-12 Converts “Cold” to “Hot” in Other Solid Tumor Types Merkel Cell Carcinoma Head & Neck Cancer Pre-ImmunoPulse® IL-12 Post-ImmunoPulse® IL-12 Pre-ImmunoPulse® IL-12 Post-ImmunoPulse® IL-12 “LowTIL” “High”TIL “LowTIL” “High”TIL CD8 –Green Foxp3 –White FoxP3 –Green CD3 - Pink PD-L1

  11. Slide 11: Phase 2 Combo Data in Low TIL: Best Response in Anti-PD-1 Cold Tumors

    // ImmunoPulse® IL-12 Phase 2 Combo Data in Low TIL: Best Response in Anti-PD-1 Cold Tumors to Date • 50% BORR at 48 weeks + 38.1% CR (RESIST v1.1) with ImmunoPulse IL-12 + anti-PD-1 in patients unlikely to respond to anti-PD-1 monotherapy* – ~10% response expected with anti-PD-1 • Subset of patient

  12. Slide 12: PISCES: Clinical Trial Collaboration with Merck & Co.

    // PISCES: Clinical Trial Collaboration with Merck & Co. A leading biotechnology company developing DNA-based intratumoral Collaboration Highlights immunotherapies • Access to key clinical and development expertise • Provide Keytruda® throughout the study • Joint development committee Global leader

  13. Slide 13: PISCES: ImmunoPulse IL-12 for Stage III/IV Melanoma

    // PISCES: ImmunoPulse ® IL-12 for Stage III/IV Melanoma Primary outcome may support BLA for accelerated approval in 2019 Anti-PD-1 IL-12 Stage III/IV Combination Electroporation Study  Orphan designation • Single Arm Phase 2/3 study, Simon 2 stage minimax design  Fast Track - 4 responders out of

  14. Slide 14: Favorable PISCES Data Could Unlock ~10K Stage III/IV Melanoma Anti-PD-1 Failure Patients

    // Favorable PISCES Data Could Unlock ~10K Stage III/IV Melanoma Anti-PD-1 Failure Patients (US Only) • Combo therapy with checkpoint 1st Line 2nd Line 3rd Line inhibitors rapidly becoming SOC in cancer 9.9K 4.0K 1.8K • Checkpoint products becoming backbone therapy for ~60% or more Anti-PD-1 Respond

  15. Slide 15: ImmunoPulse IL-12 Target Product Profile Potentially Superior to Other Agents

    // ImmunoPulse ® IL-12 Target Product Profile Potentially Superior to Other Agents Under Development Intratumoral Delivery Systemic Delivery • Delivery of plasmid DNA using proprietary device • Isolated TIL from patients tumor Cytokine • Fast-track and orphan designation • Fast-track designation • P

  16. Slide 16: ImmunoPulse IL-12: the Next Innovation for Oncology

    // ImmunoPulse® IL-12: the Next Innovation for Oncology ImmunoPulse IL-12 demonstrated good Safety safety and tolerability; no additive or new AE/SAE in combination trials to date Safety Efficacy ImmunoPulse IL-12 has shown local and Efficacy systemic response in PD-I predicted non responders Improv

  17. Slide 17: OncoSec ImmunoPulse Electroporation Platform

    // OncoSec ImmunoPulse® Electroporation Platform ImmunoPulse® DNA plasmids Electric pulses Product expression designed to boost the coded to produce increase permeability of cells produce proteins to immune system to immune modulatory cell membrane, enhance immunomodulatory recognize and attack prot

  18. Slide 18: Protecting and Enabling Next Generation Technology to Address Interior Tumors

    // Protecting and Enabling Next Generation Technology to Address Interior Tumors IP and FTO OncoSec GENESIS™ + TRACE™ • Issued patents on plasmid/ • Tissue-Based Real-Time electroporation combination to Adaptive Control Electroporation treat cancer, including melanoma • Electrochemical properties of

  19. Slide 19: Executing on Key Milestones

    // Executing on Key Milestones NEAR-TERM VALUE CREATING MILESTONES  Initiate global Ph 2 PISCES trial • PISCES stage 1 enrollment Early efficacy in Ph 2 trial complete Fast Track & Orphan Designation in • PISCES initial BORR data mid-2018 melanoma • EOP2 with FDA; seek feedback on • SITC/SMR clin

  20. Slide 20: A Leader in Intratumoral Cancer Immunotherapies

    // OncoSec A Leader in Intratumoral Cancer Immunotherapies Multiple near-term clinical milestones Addressing important unmet medical need Highly experienced team; enhanced BOD 28M outstanding shares $11.4M cash as of June 30, 2017 • 20 •

  21. Slide 21: Thank you

    Thank you Company Contacts October 2017 855-662-6732 investors@oncosec.com www.oncosec.com • 21 •

OncoSec Medical — Investor Presentation (October 2017) on 6ix